Stock listing

NASDAQ:IKT Inhibikase Therapeutics, Inc. Stock

Home listing (NASDAQ) of Inhibikase Therapeutics, Inc.

Follow Inhibikase Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IKT

$1.71 USD +0.06 (+4.0%)

Close on Oct 20, 2026

Past 3 months -13.6% · daily closes, Jul 6, 2026 – Oct 20, 2026, adjusted for splits
Day range
$1.63 – $1.75 USDOct 20, 2026
Volume
352,242 sharesOct 20, 2026
Market cap
$238.6M USDAt the close on Oct 20, 2026 · price × 139.5M shares outstanding
Inhibikase Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IKT · Home$1.71 USD+0.065 (+4.0%)352,242$1.65$1.75$1.63$1.645Close on Oct 20, 2026

Daily closes

Last 3 months, Jul 20, 2026 – Oct 20, 2026 · NASDAQ:IKT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.71+0.065+4.0%$1.65$1.75$1.63352,242
$1.645-0.005-0.3%$1.67$1.72$1.571,330,173
$1.65-0.18-9.8%$1.82$1.82$1.65917,213
$1.83+0.03+1.7%$1.80$1.869$1.795400,740
$1.80+0.04+2.3%$1.73$1.865$1.721,578,885
$1.76-0.085-4.6%$1.85$1.875$1.731,163,500
$1.845-0.125-6.3%$1.95$1.95$1.77741,195
$1.97+0.06+3.1%$1.90$1.98$1.87435,034
$1.91-0.03-1.5%$1.94$1.94$1.86417,264
$1.94-0.04-2.0%$1.95$2.00$1.925444,047
$1.98-0.02-1.0%$1.97$2.04$1.95583,800
$2.000.000.0%$2.00$2.025$1.955407,300
$2.00+0.07+3.6%$1.96$2.016$1.932434,500
$1.93-0.125-6.1%$2.095$2.095$1.93474,700
$2.055+0.035+1.7%$2.03$2.08$1.99579,500
$2.02-0.03-1.5%$2.03$2.05$2.005400,300
$2.05-0.01-0.5%$2.05$2.065$1.94765,100
$2.06-0.04-1.9%$2.10$2.15$2.045447,200
$2.10-0.05-2.3%$2.15$2.17$2.08499,100
$2.15-0.16-6.9%$2.30$2.31$2.14412,300
$2.31+0.11+5.0%$2.23$2.335$2.21468,700
$2.20-0.10-4.3%$2.31$2.32$2.195366,000
$2.300.000.0%$2.31$2.345$2.283,209,700
$2.30-0.01-0.4%$2.31$2.365$2.285475,500
$2.310.000.0%$2.32$2.345$2.26370,500
$2.31-0.08-3.3%$2.40$2.40$2.253480,900
$2.39+0.05+2.1%$2.34$2.425$2.34482,900
$2.34+0.01+0.4%$2.37$2.39$2.323303,200
$2.33-0.08-3.3%$2.37$2.385$2.32332,400
$2.41-0.02-0.8%$2.43$2.45$2.38323,400
$2.43-0.07-2.8%$2.45$2.525$2.43310,500
$2.50-0.02-0.8%$2.49$2.55$2.475247,000
$2.52+0.02+0.8%$2.50$2.61$2.46564,200
$2.50+0.12+5.0%$2.39$2.535$2.39379,000
$2.38+0.07+3.0%$2.30$2.405$2.27523,200
$2.31-0.10-4.1%$2.41$2.44$2.30329,900
$2.41-0.06-2.4%$2.48$2.48$2.371308,000
$2.47-0.02-0.8%$2.48$2.50$2.40202,000
$2.49-0.01-0.4%$2.50$2.51$2.43244,100
$2.500.000.0%$2.53$2.54$2.46453,435
$2.50+0.11+4.6%$2.41$2.54$2.345735,926
$2.39+0.04+1.7%$2.38$2.415$2.37309,300
$2.35-0.10-4.1%$2.45$2.47$2.33540,000
$2.45+0.05+2.1%$2.44$2.515$2.43645,000
$2.40+0.01+0.4%$2.36$2.41$2.31344,000
$2.39-0.02-0.8%$2.41$2.42$2.32489,500
$2.410.000.0%$2.39$2.435$2.37227,900
$2.41+0.01+0.4%$2.43$2.46$2.33360,700
$2.40-0.05-2.0%$2.38$2.47$2.38296,900
$2.45-0.01-0.4%$2.48$2.515$2.41580,700
$2.46-0.01-0.4%$2.44$2.525$2.42479,000
$2.47+0.06+2.5%$2.38$2.475$2.38386,700
$2.41+0.01+0.4%$2.39$2.49$2.385422,900
$2.40-0.04-1.6%$2.46$2.50$2.331,108,500
$2.44+0.23+10.4%$2.25$2.465$2.241,255,000
$2.21+0.03+1.4%$2.19$2.285$2.155486,500
$2.18-0.10-4.4%$2.27$2.285$2.13369,500
$2.28+0.07+3.2%$2.21$2.32$2.185402,600
$2.21-0.10-4.3%$2.31$2.33$2.17684,800
$2.31-0.04-1.7%$2.35$2.39$2.27472,000
$2.35+0.02+0.9%$2.36$2.39$2.315513,900
$2.330.000.0%$2.37$2.53$2.322,158,400
$2.33+0.16+7.4%$2.13$2.34$2.121,347,700
$2.17-0.06-2.7%$2.20$2.25$2.15632,100
$2.230.000.0%$2.23$2.32$2.18901,335
$2.23+0.12+5.7%$2.11$2.26$2.101,072,648
Ticker
NASDAQ:IKT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Inhibikase Therapeutics (NASDAQ:IKT) Q2 2024 Earnings Call

    Thu, Aug 15, 2024 · 8:00 AM ET

    Watch Transcript
  • Inhibikase Therapeutics (NASDAQ:IKT) Q1 2024 Earnings Call

    Thu, May 16, 2024 · 8:00 AM ET

    Watch Transcript
  • Inhibikase Therapeutics (NASDAQ:IKT) Q4 2023 Earnings Call

    Thu, Mar 28, 2024 · 8:00 AM ET

    Watch Transcript

Latest news

All Inhibikase Therapeutics, Inc. news

Financings

  • At-the-market programme of common stock

    Aug 11, 2026

    Closed: US$50M in the latest tranche

    Buyers: RA Capital Management (25,000,000 shares of common stock for gross proceeds of $50 million)

    Use of proceeds: With existing cash, to support operations through topline data readout in Part B of the Phase 3 IMPROVE-PAH study

    Closed Jul 14, 2026 · Closed Jul 15, 2026 · Closed Aug 11, 2026

Read by 6ix AI from the company's releases

Decks

Inhibikase Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 27 in all · newest Oct 20, 2026 · oldest 2024
Calls
11 calls with a replay · 11 with a transcript · latest Aug 15, 2024
Decks
14 decks · latest September 2026

Where Inhibikase Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IKT · Home listing · This pageNASDAQUnited StatesUSD
gettex:IQT0gettexGermanyEUR
BOATS:IKTBOATSUnited StatesUSD
Munich:IQT0MunichGermanyEUR
Stuttgart:IQT0StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Inhibikase Therapeutics, Inc.